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Objective. Little is known about the information providers share with patients when ordering a co-test, or
combined human papillomavirus (HPV) and Papanicolaou (Pap) test, for cervical cancer screening. We assessed
provider perceptions of such communication practices with female patients aged 30–60 years.
Methods.We analyzed data from 98 providers in 15 Federally Qualiﬁed Health Center clinics across Illinois
(2009–2010).
Results. About 70% of the providers reported that when ordering a co-test, they would usually or always com-
municate information about the HPV test to their patients, explain the test detects a sexually transmitted infec-
tion, and discuss how the test results may determine their next screening interval. Most (N85%) reported that
they were comfortable discussing co-test results. Compared with concordant positive results (HPV positive/
Pap positive), providers were more likely to perceive that discordant results (HPV positive/Pap negative)
would be too complex for patients to understand (25% vs. 15%, p = 0.006), and make patients feel less assured
that they were getting the best standard of care (67% vs. 88%, p b 0.001).
Conclusion. As HPV testing plays a more prominent role in cervical cancer screening, more attention should
be given to communications between providers and patients about the beneﬁts and harms of different
screening options.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Current cervical cancer screening recommendations state that
average-risk women aged 30–65 years have a Papanicolaou (Pap) test
alone every 3 years or a combination of human papillomavirus (HPV)
and Pap test (i.e., co-test) every 5 years (ACOG Committee on Practice
Bulletins-Gynecology, 2012; Saslow et al., 2012; US Preventive Services
Task Force, 2012). The current recommendationshave caused confusion
among providers and patients about the appropriate screening options
(Hawkins et al., 2013; Roland et al., 2013), presenting challenges in clin-
ical implementation. Recent studies showed that the overall propor-
tions of co-testing have gradually increased (Phelan et al., 2011; Tatsas
et al., 2012), indicating that providers are incorporating the HPV test
into their screening practices. As co-testing has becomemore prevalent,
it is important to understand what information providers share with
their patients when ordering the co-test. The study objectives were to
assess provider perceptions of 1) their communication practices aboution and Control, Epidemiology
l and Prevention, 4770 Buford
. This is an open access article underthe co-test, and 2) the risks and beneﬁts of discussing co-test results
with female patients aged 30–60 years.Methods
The Centers for Disease Control and Prevention (CDC) launched the
CDCCervical Cancer (Cx3) Study to survey both provider and patient at-
titudes and beliefs regarding the co-test (Benard et al., 2014; Roland
et al., 2013). The study was conducted in 15 clinics associated with six
Federally Qualiﬁed Health Centers (FQHCs) across Illinois. FQHCs were
selected as the study site because the client base is predominately low
income and under- or uninsured, and assessing practices in these
settingswill help CDC provide technical assistance to its national cancer
programs. Of note, the survey took place between 2009 and 2010, at
which time the cervical cancer screening guidelines recommended
screening every 3 years in women aged 30–65 years who had either a
negative co-test or three consecutive negative screening tests (Smith
et al., 2010). Baseline surveyswere completed by 98providers including
physicians, nurse practitioners, certiﬁed nurse midwives, and physician
assistants (89.9% response rate). Providers were eligible to participate if
they personally performed Pap testing for routine cervical cancerthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
437L. Lin et al. / Preventive Medicine Reports 2 (2015) 436–439screening. A $50 cash incentive was given to providers for their partici-
pation. This study was approved by CDC's Institutional Review Board.
Communication practices were assessed by asking a series of ques-
tions, with response options ranging from never to always: If you
order a co-test, how often would you:
a) Tell the patient that you are ordering an HPV test?
b) Explain to the patient the purpose of an HPV test in relation to the
Pap test?
c) Explain to the patient that the HPV test detects a sexually transmit-
ted infection?
d) Discuss with the patient how HPV test results may determine when
she will need to be screened for cervical cancer again?
In addition, eleven statements were developed to assess provider
perceived risks and beneﬁts of discussing co-test results with patients
(Fig. 1). Statements were presented in two sections: discordant results
(HPV positive/Pap negative) and concordant positive results (HPV pos-
itive/Pap positive). Providers were instructed to indicate the extent to
which they agree or disagree with each statement. For example, pro-
viders were asked if they agreed, disagreed, or were neutral regarding
a discordant result statement such as, “Discussing with patients the re-
sults of a positive HPV test and a normal Pap test would… assure pa-
tients that they are getting the best standard of care.”
Descriptive statistics are presented for all measures. We used the
exact McNemar's test to detect signiﬁcant differences (p b 0.05)
between provider responses to the discussion of discordant and
concordant positive results. For the McNemar's test, responses were
transformed into binary measures of “agree” vs. “neither/disagree.”Fig. 1. Provider perceived risks and beneﬁts of discussing co-test results with female patients ag
icant differences (p b 0.05) between provider responses to the discussion of discordant and co
Two-tailed exact McNemar's test compares the proportion “agree” vs. “neither/disagree.” StudAnalyses were conducted using Stata (Release 13, StataCorp LP, College
Station, TX, USA).Results
Providers were predominantly female (77%). Most were physi-
cians (66%) or nurse practitioners (20%), were trained in obstetrics/
gynecology (53%) or family medicine (36%), and had an average of
8.8 years providing clinical care (N = 98, not reported in a table or
ﬁgure).
When ordering a co-test, providers reported that they would
usually or always explain the purpose of an HPV test in relation to
the Pap test (75%), discuss how HPV test results may determine when
the patient will need to be screened for cervical cancer again (75%),
tell the patient that they are ordering an HPV test (72%), and explain
that the HPV test detects a sexually transmitted infection (69%)
(Table 1).
The perceived risks and beneﬁts of discussing co-test results are
shown in Fig. 1. Overall, providers reported that they were comfortable
discussing co-test results with patients (discordant: 88%; concordant
positive: 92%). Some risks perceived by providers included raising
patient concerns about partner ﬁdelity (discordant: 71%; concordant
positive: 66%), and making them feel uncomfortable, upset, or angry
(discordant: 40%; concordant positive: 40%). Comparedwith discussing
concordant positive results, providers were more likely to perceive
that discussing discordant results would be too complex for patients
to understand (25% vs. 15%, p = 0.006), and make patients feel less
assured that they were getting the best standard of care (67% vs. 88%,
p b 0.001).ed 30–60 years, 2009–2010 (n= 95–97). Abbreviation: Pap= Papanicolaou test. *Signif-
ncordant positive results. **Percentages may not total to 100 because of rounding. Notes:
y was conducted in 15 Federally Qualiﬁed Health Center clinics in Illinois, USA.
Table 1
Provider reported communication practices about ordering the co-test, or combined human papillomavirus and Papanicolaou test, for female patients aged 30–60 years, 2009–2010 (n= 97).
Discussion content Always or
usually
Half the time or
sometimes
Never
Explain to the patient the purpose of an HPV test in relation to the Pap test 75% 21% 4%
Discuss with the patient how HPV test results may determine when she will need to be screened for cervical cancer again 75% 23% 2%
Tell the patient that you are ordering an HPV test 72% 23% 5%
Explain to the patient that the HPV test detects a sexually transmitted infection 69% 27% 4%
Abbreviation: HPV= human papillomavirus.
Note: Study was conducted in 15 Federally Qualiﬁed Health Center clinics in Illinois, USA.
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About 70% of the 97 providers in our study reported that when or-
dering a co-test for cervical cancer screening, they would usually or
always communicate information about the HPV test to their patients,
explain that the test detects a sexually transmitted infection, and dis-
cuss how HPV test results may determine their next screening interval.
However, in studies of patient perceptions of provider educational ef-
forts regarding HPV, patients reported not being educated well during
their routine exams (Blake et al., 2015; Cermak et al., 2010). They stated
that speciﬁc HPV topics, such as the differences between the HPV and
Pap tests, risk factors associated with HPV infection, and preventive
measures were not mentioned (Cermak et al., 2010). It is therefore es-
sential that information regarding cervical cancer screening options be
provided to patients clearly, to ensure that patients understand the dis-
ease and their choices for management. Providers may also increase
patient involvement in making clinical decisions that are consistent
with individuals' preferences and values while promoting recommend-
ed guidelines. Strategies such as communication training, decision aids,
or patient educationmay bewarranted to facilitate this process (Harper,
2004).
Overall, providers in our study were comfortable discussing co-test
results with patients. In comparison with the discussion of concordant
positive results, providers were more likely to perceive that the discus-
sion of discordant results would be too complex for patients to under-
stand, and make patients feel less assured that they were getting the
best standard of care. This could be because of the options available
for follow-up management in the case of discordant results. Whereas
womenwith concordant positive results are referred directly for colpos-
copy, women with discordant results either wait 12 months for repeat
co-testing or undergo HPV genotype-speciﬁc testing for types 16/18,
according to the current guidelines (Massad et al., 2013). Immediate re-
ferral for colposcopy for women with discordant results is not recom-
mended because the risk for imminent cancer is low (Katki et al.,
2011). However, one concern is that womenmay not return the follow-
ing year, resulting in loss to follow-up, particularly for those with lower
socioeconomic status (Saraiya et al., 2014).
Some commonly perceived risks inherent to the discussion of co-test
results included raising patient concerns about partner ﬁdelity, and
making them feel uncomfortable, upset, or angry. The reported con-
cerns are consistent with patient experiences on receiving an HPV pos-
itive result (McCaffery et al., 2006). One study found that the adverse
social and psychological consequences resulting from testing positive
for HPV were beyond those experienced by abnormal Pap test results
alone (McCaffery et al., 2006). The sexually transmitted nature of the
HPV virus has led to stigma, anxiety, and concern about sexual relation-
ships (McCaffery et al., 2006). Emphasizing the high prevalence of HPV
may reduce the negative psychosocial consequences of testing positive
for HPV (Waller et al., 2007). Continued efforts are needed to educate
patients about how common HPV is in the general population.
This is one of the few studies to assess provider communication
practices about the co-test. Limitations of this study include the small
sample size of providers, the use of self-reported data, and the primary
focus on the perceptions of provider behaviors, as opposed to their actu-
al practices. Providers were recruited from six FQHCs and are notmeantto be representative of all FQHCs in Illinois. Further research may repli-
cate the design of this study to compare with non-FQHC settings. The
survey was conducted before the 2012 changes in practice guidelines
and may not reﬂect provider responses to the revised recommenda-
tions. However, this is unlikely to have had a signiﬁcant impact, as the
guidelines advocated for less frequent screeningwith co-testing and re-
cent literature continued to show that providers have been slow to
adopt the changing guidelines (Teoh et al., 2015; Verrilli et al., 2014).
This study in turn contributes to the literature by serving as a baseline
for future studies aimed at assessing and improving provider communi-
cation practices about HPV testing. As HPV testing plays a more promi-
nent role in cervical cancer screening, more attention should be given to
communication between providers and patients about the beneﬁts and
harms of different screening options.
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